Table 1 Comparative efficacy and safety between infliximab and vedolizumab in patients with Crohn’s disease
Outcome | Treatment | Participants, N | Infliximab, estimate (95% CI)a | Heterogeneity (%) |
|---|---|---|---|---|
Efficacy: Induction phase (Week 6) | ||||
CDAI-70 | Infliximab | 220 | 72% (66%, 77%) | 0 |
Vedolizumab | 214 | 45% (32%, 60%) | 89 | |
CDAI-100 | Infliximab | 273 | 62% (56%, 68%) | 0 |
Vedolizumab | 423 | 36% (29%, 44%) | 68 | |
Clinical remission | Infliximab | 611 | 38% (32%, 45%) | 69 |
Vedolizumab | 423 | 17% (12%, 24%) | 71 | |
Efficacy: Maintenance phase (Week 50 to 54) | ||||
CDAI-70 | Infliximab | 220 | 74% (68%, 79%) | 0 |
CDAI-100 | Infliximab | 273 | 70% (64%, 75%) | 0 |
Vedolizumab | 148 | 44% (24%, 67%) | 93 | |
Clinical remission | Infliximab | 611 | 54% (48%, 60%) | 57 |
Vedolizumab | 148 | 39% (24%, 56%) | 88 | |
Safety (≤ 1 year) | ||||
Any AE | Infliximab | 717 | 75% (66%, 83%) | 86 |
Vedolizumab | 985 | 78% (59%, 90%) | 98 | |
Any SAE | Infliximab | 717 | 12% (8%, 17%) | 65 |
Vedolizumab | 993 | 16% (8%, 30%) | 93 | |
Any infection | Infliximab | 717 | 29% (22%, 37%) | 80 |
Vedolizumab | 427 | 17% (14%, 21%) | 24 | |
Any serious infection | Infliximab | 562 | 4% (2%, 6%) | 0 |
Vedolizumab | 985 | 4% (2%, 8%) | 67 | |
Discontinuation due to AE | Infliximab | 717 | 6% (3%, 12%) | 79 |
Vedolizumab | 976 | 7% (3%, 15%) | 84 | |
Discontinuation due to lack of efficacy | Infliximab | 311 | 6% (4%, 10%) | 49 |